FIELD: medicine.
SUBSTANCE: invention relates to experimental medicine, general toxicology and nanotoxicology, and concerns criteria for diagnosis of toxic action of silver nanoparticles encapsulated in a natural polymer matrix of arabinogalactan (AG) on brain tissue of rats in long term. Method comprises exposing animal test group to toxicant by intragastric administration of an aqueous solution of AG with silver nanoparticles (nano-Ag-AG) in amount of 100 mcg per kilogram of silver in 0.5 ml of distilled water for 9 days. Control animals a subjected to intragastric administration of 0.5 ml of distilled water and for 9 days. After 6 months sectioning of cortex tissue from both groups of animals is performed. Stained with antibody to protein caspase-3, and survey microscopy of obtained preparations is performed. Number of pathologically altered neurons without expression of caspase 3, number of pathologically altered neurons expressing caspase 3, number of normal neurons without expression of caspase 3, number of normal neurons expressing caspase 3, total number of neurons per unit cut area is determined. Ratio of said indicators on preparations of experimental group to that of control group on preparations is calculated. By increasing number of pathologically altered neurons without expression of caspase 3 by 1.6 times relative to control group, increase in number of pathologically altered neurons expressing caspase 3 by 2.7 times relative to control group, reducing number of normal neurons without caspase 3 0.6 times in relation to control group, increase in number of normal neurons expressing caspase 3 2-fold relative to control group as well as reducing total number of neurons per unit area of 0.5 times relative to control group of development of inferring pathological process predominant damage type apoptosis in brain tissue in long term effects of nano-Ag-AG.
EFFECT: method improves accuracy of verification toxic encephalopathies, including due to registration of functional changes of morphometric characteristics of neurons.
1 cl, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF ESTIMATION OF THE APOPTOSIS PROCESS IN THE FABRIC OF THE BRAIN OF LABORATORY ANIMALS | 2016 |
|
RU2621122C1 |
METHOD OF ASSESSING THE TOXIC EFFECT OF A BIMETALLIC FERRUM-GADOLINIUM NANOCOMPOSITE ENCAPSULATED IN A NATURAL POLYMER MATRIX OF ARABINOGALACTAN ON LABORATORY ANIMALS | 2019 |
|
RU2733504C1 |
METHOD FOR ESTIMATING THE TOXICITY OF MICRO- AND NANOPARTICLES BY THE MORPHOLOGICAL FEATURES THEREOF | 2020 |
|
RU2756524C1 |
DIAGNOSTIC TECHNIQUE FOR MERCURY ENCEPHALOPATHY IN SMALL LABORATORY ANIMALS | 2011 |
|
RU2471247C1 |
METHOD FOR ASSESSING COPPER NANOPARTICLES ADMINISTRATION SAFETY | 2011 |
|
RU2477485C2 |
APPLICATION OF (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINES IN DEMENTIA AND PARKINSON'S DISEASE TREATMENT | 2003 |
|
RU2332218C2 |
MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
GENE-CELL VESICULAR THERAPEUTIC DRUG AND METHOD FOR MULTIPLE SCLEROSIS THERAPY BY TRANSPLANTATION OF A GENE-CELL VESICULAR THERAPEUTIC DRUG | 2021 |
|
RU2762855C1 |
MEANS OF CHRONIC VENOUS INSUFFICIENCY TREATMENT | 2022 |
|
RU2797950C1 |
METHOD OF DETECTING PRESENCE OF SYSTEMIC REACTION OF CONNECTIVE TISSUE, CONDITIONED BY DEVELOPMENT OF SYNDROME OF COMBINED DYSTROPHIC-DEGENERATIVE CHANGES OF MESENCHYMAL DERIVATIVES IN CASE OF LOCAL CHRONIC INFLAMMATORY PROCESS | 2012 |
|
RU2493777C1 |
Authors
Dates
2016-03-27—Published
2015-01-12—Filed